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Pretreatment Lymphopenia, Poor Performance Status, and Early 
Courses of Therapy Are Risk Factors for Severe Bacterial Infection 
in Patients with Multiple Myeloma during Treatment with 
Bortezomib-based Regimens
The aim of this study was to identify the risk factors associated with severe bacterial 
infection (SBI) in multiple myeloma (MM) patients during treatment with bortezomib-
based regimens. A total of 98 patients with MM were evaluated during 427 treatment 
courses. SBI occurred in 57.1% (56/98) of the patients and during 19.0% (81/427) of the 
treatment courses. In the multivariate analysis for the factors associated with the 
development of SBI in each treatment course, poor performance status (Eastern 
Cooperative Oncology Group ≥ 2, P < 0.001), early course of therapy (≤ 2 courses, 
P < 0.001), and pretreatment lymphopenia (absolute lymphocyte count < 1.0 × 109/L, 
P = 0.043) were confirmed as independent risk factors. The probability of developing SBI 
were 5.1%, 14.9%, 23.9%, and 59.5% in courses with 0, 1, 2, and 3 risk factors, 
respectively (P < 0.001). In conclusion, we identified three pretreatment risk factors 
associated with SBI in each course of bortezomib treatment. Therefore, MM patients with 
these risk factors should be more closely monitored for the development of SBI during 
bortezomib-based treatment.
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INTRODUCTION
Infection is the leading cause of morbidity and mortality in mul-
tiple myeloma (MM), in which 26%-45% of early deaths are at-
tributable to infection (1,2). Infection is not only the direct cause 
of death but also affects disease progression due to the delaying 
of planned anti-myeloma therapy. The risk of bacterial infection 
increases 7-fold in patients with MM compared with matched 
controls (2), and the increased susceptibility to infection is due 
to disease-related immune deficits on innate and adaptive im-
mune system including hypogammaglobulinemia (3,4), renal 
failure (3), treatment-related toxicities (4,5), and the use of high-
dose corticosteroid therapy (6).
  The treatment of MM has undergone a paradigm shift with 
the use of immunomodulatory drugs (thalidomide, lenalido-
mide, and pomalidomide) and proteasome inhibitors (bort-
ezomib) (7). The effects of these drugs on the immune system 
are distinct from those of conventional anti-myeloma agents. In 
addition, these drugs are usually used in combination with high-
dose dexamethasone, resulting in impairment of cell-mediated 
immunity. Therefore, the types and patterns of infections have 
changed by the administration of these novel agents. Bortezo-
mib suppresses essential T-cell mediated immune responses 
by inhibiting the functions of human CD4+ T cells (8,9), reduc-
ing antigen presentation by CD8+ T cells, and reducing the cy-
totoxic T cell response (10). Consequently, the incidence of var-
icella zoster virus infection increased in patients treated with 
bortezomib-based regimens compared with those treated with 
melphalan plus prednisone (11) or with high-dose dexametha-
sone (12). In contrast to viral infections, the incidence of bacte-
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rial infections was similar (10%-13%) (11,13) to that of regimens 
with melphalan plus prednisone (7%-10%) (14,15) but lower 
than that of regimens with intensive chemotherapeutic agents 
such as VAD (vincristine, doxorubicin, and dexamethasone) 
(14%-27%) (16,17) and DCEP (dexamethasone, cyclophospha-
mide, etoposide, and cisplatin) (7.5%-22.5%) (18).
 As the types and patterns of infections change, the risk factors 
for severe bacterial infection (SBI) in the MM patients treated 
with bortezomib-based regimens may be different from previ-
ously known risk factors. The risk of bacterial infection increased 
in the early period of treatment with high tumor burden and 
decreased with a favorable response because of the restoration 
of the immune deficit (16). Therefore, a comprehensive pretreat-
ment assessment of the risk factors for SBI in each treatment 
course can discriminate the patients at increased risk of SBI and 
allow the application of patient-oriented prophylactic and ther-
apeutic approaches for SBI.
 In this study, we analyzed the various clinical and laboratory 
parameters that were associated with infectious complications 
to determine the risk factors for SBI in 98 MM patients treated 
with bortezomib-based regimens during 427 treatment courses. 
MATERIALS AND METHODS
Patient eligibility
A total of 98 consecutive patients diagnosed with MM and who 
were treated with upfront or salvage bortezomib-based treat-
ments in the Severance Hospital between January 2006 and De-
cember 2012 were included. In the cases of patients treated with 
more than one bortezomib-based regimen as a different line of 
therapy, we used only the data related to the first bortezomib-
based regimen. This study was approved by the Institutional 
Review Board of the Severance Hospital.
Treatment protocol and schedule
We retrospectively analyzed the data of 427 bortezomib treat-
ment courses in 98 MM patients. Of the 98 MM patients, 58 pa-
tients received bortezomib (1.3 mg/m2 intravenously [i.v.] on 
days 1, 4, 8, and 11) and dexamethasone (40 mg/day on days 
1-4) every 3 weeks (VD regimen). Twenty-five patients received 
bortezomib (1.3 mg/m2 i.v. on days 1, 4, 8, 11, 22, 25, 29, and 32 
during courses 1 to 4 and on days 1, 8, 22, and 29 during cours-
es 5 to 9), melphalan (9 mg/m2 via oral route on days 1-4), and 
prednisolone (60 mg/m2 via oral route on days1-4) every 6 weeks 
(VMP regimen). To simplify the statistical analysis, one VMP 
regimen was divided into 2 courses, each with a 3-week sched-
ule, and the VMP regimen variables presented are based on 1 
course with a 3-week schedule. Fifteen patients received bort-
ezomib (1.3 mg/m2 i.v. on days 1, 4, 8, and 11), doxorubicin (9 
mg/m2 i.v. on days 1-4), and dexamethasone (40 mg on days 
1-4) every 3 weeks (PAD regimen). Antibacterial prophylaxis 
was not routinely administered but a prophylactic antibacterial 
agent (ciprofloxacin or levofloxacin) was used in 70.4% of the 
patients and a prophylactic antifungal agent (fluconazole) was 
used in 64.3% of the patients before or immediately after start-
ing chemotherapy according to each physician’s decision. No 
patient received antiviral prophylaxis in this study. 
Definitions
We investigated infectious complications and treatment-related 
toxicities within 1 month after each bortezomib course and the 
data from that period were analyzed. Chemotherapy-related 
toxicities were graded according to the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events (CTCAE) 
version 4.0. SBI was defined as grade 3-5 infection of each sys-
tem or neutropenic fever. We divided patients into two groups: 
1) the SBI group, composed of patients who developed SBI dur-
ing the bortezomib treatment, 2) the non-SBI group, composed 
of patients who did not develop SBI during the bortezomib treat-
ment. SBI was classified into three categories: 1) clinically doc-
umented infection (CDI), for the cases in which clinical signs 
and symptoms of infection were present although the culture 
results were negative, 2) microbiologically documented infec-
tion (MDI), for the cases in which pathogens were isolated from 
a blood sample or other cultures, 3) fever of unknown origin 
(FUO), for the cases in which fever was the only sign of infec-
tion. In defining CDI and FUO, the episodes which were highly 
suspicious for bacterial infection were included and document-
ed viral or fungal infections were excluded. Lymphopenia was 
defined as an absolute lymphocyte count (ALC) of < 1.0 × 109/
L. Mortality was defined as infection-related death regardless of 
refractory or progressive disease.
 Response to treatment was assessed according to the Inter-
national Myeloma Working Group uniform response criteria 
(19). Progression-free survival (PFS) after bortezomib treatment 
was measured from the initial date of bortezomib treatment to 
the date of progression or the final follow-up visit without pro-
gression or the date of death. Overall survival (OS) after bort-
ezomib treatment was measured from the initial date of bort-
ezomib treatment to the final follow-up date or the date of death 
from any cause.
Statistical analysis
To identify the risk factors for the development of SBI during 
bortezomib treatment, we analyzed the variables using two ap-
proaches: 1) analysis of the patients who developed SBI during 
a specific period of treatment (total, 2 courses, or 3 months), or 
2) analysis of each bortezomib treatment course. 
 Continuous variables were compared using Mann-Whitney 
U test and categorical variables were compared using χ2 test or 
Fisher’s exact test. Univariate analysis for the factors that affect-
ed the development of SBI was performed using a logistic re-
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gression method. The factors with P < 0.1 were selected and in-
cluded in the multivariate logistic regression analysis. Potential 
confounding factors and multicollinearity were evaluated, and 
the factors strongly associated with other significant factors were 
excluded from the multivariate analysis. The survival curves 
were calculated using the Kaplan-Meier method and were com-
pared using the log-rank test. A P value of < 0.05 was defined as 
statistically significant. All statistical calculations were performed 
with the PASW software version 20.0 (IBM Corp., Armonk, NY, 
USA).
Ethics statement
The protocol was approved by severance hospital’s institutional 
review board (4-2013-0441). The data of this study was obtained 
from large numbers of patients for a retrospective chart review 
study so informed consent was waived.
RESULTS
Patient characteristics
The clinical characteristics of the 98 patients are summarized in 
Table 1. Ninety-eight patients received a median of 4 treatment 
courses (range, 1-15) of bortezomib-based chemotherapy and 
a total of 427 bortezomib courses. Most of the clinical charac-
teristics were not significantly different between the SBI group 
and the non-SBI group except the performance status.
Table 1. Clinical characteristics of the 98 patients undergoing chemotherapy with the bortezomib-containing regimen
Variables
No. (%) of patients by group
P value
Total SBI group Non-SBI group
At the time of diagnosis
Total number of patients 98 56 42
Age, yr 61 (39-80) 61 (39-76) 60 (42-80) 0.146
Gender
   Male
   Female
53 (54.1)
45 (45.9)
26 (46.4)
30 (53.6)
27 (64.3)
15 (35.7)
0.060
Type of monoclonal component
   IgG
   IgA
   IgD
   Light chain only
57 (58.2)
19 (19.4)
4 (4.1)
18 (18.4)
35 (62.5)
11 (19.6)
1 (1.0)
9 (16.1)
22 (52.4)
8 (19.0)
3 (7.1)
9 (21.4)
0.477
Plasma cell (%) in bone marrow ≥ 50% 25 (45.5) 10 (35.7) 15 (55.6) 0.140
Durie-Salmon stage
   I
   II
   III
3 (3.1)
9 (9.2)
86 (86.7)
2 (3.6)
4 (7.3)
49 (89.1)
1 (2.4)
5 (11.9)
36 (85.7)
0.704
Renal dysfunction (creatinine ≥ 2 mg/dL) 22 (22.4) 14 (25.5) 8 (19.0) 0.310
ISS stage*
   I, II
   III
33 (33.6)
58 (59.2)
17 (32.7)
35 (67.3)
16 (41.0)
23 (59.0)
0.274
At the time of bortezomib treatment initiation
Age, yr 62 (39-80) 62 (39-78) 62 (45-80) 0.255
Disease status
   Newly diagnosed
   Relapsed/refractory
30 (31.6)
68 (68.3)
16 (28.6)
40 (71.4)
14 (33.3)
28 (66.7)
0.461
Number of prior lines of therapy
   0
   1
   2
  ≥ 3
30 (31.6)
38 (38.8)
20 (20.4)
10 (10.1)
16 (28.6)
22 (39.3)
13 (23.2)
5 (9.0)
14 (33.3)
16 (38.1)
7 (16.7)
5 (11.9)
0.970
Performance status (ECOG)† ≥ 2 35 (36.8) 28 (50.0) 7 (16.7) < 0.001
Monoclonal protein ≥ 3.0 g/dL 19 (31.7) 10 (32.3) 9 (31.0) 0.570
Decrease of uninvolved immunoglobulins 
  ≥ 1 immunoglobulin‡ 58/63 (92.1) 30/33 (90.9) 28/30 (93.3) 0.546
Regimen
   bortezomib/dexamethasone
   bortezomib/doxorubicin/dexamethasone
   bortezomib/melphalan/prednisone
58 (59.1)
15 (15.3)
25 (25.5)
34 (60.8)
7 (12.5)
15 (26.8)
24 (57.2)
8 (19.0)
10 (23.8)
0.668
Number of treatment courses 4.0 (1-15) 3.5 (1-12) 4.0 (1-15) 0.106
Follow up period after treatment, month 6.3 (0.5-57.1) 5.4 (0.5-57.6) 16.0 (0.8-55.8) 0.040
Continuous variables are presented as median (range). *Missed data in 7 patients; †Missed data in 3 patients; ‡Missed data in 35 patients. SBI, severe bacterial infection; ECOG, 
Eastern Cooperative Oncology Group; ISS, International Scoring System.
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Infection profile
Infection development was assessed in each patient and for 
each treatment course. Of the 98 patients, SBI was observed in 
56 (57.2%) patients, and 18 (18.3%) patients developed SBI more 
than once. Of the 427 treatment courses, 81 SBI cases occurred 
and the incidence of SBI per treatment course was 19.0%. Reac-
tivation of herpes zoster viruses developed in 13 (13.3%) patients 
and in 14 (3.0%) treatment courses. Fungal infections, defined 
as proven or probable invasive fungal disease, developed in 13 
(13.2%) patients and in 18 (4.2%) treatment courses. Most of the 
SBI episodes (79.0%) occurred in the first 3 courses and no SBI 
episode was observed after the 8th course (Fig. 1).
 Of the 81 SBI episodes, 42 (52.5%) were CDI, 30 (37.0%) were 
MDI, and 9 (11.1%) were FUO (Table 2). Pneumonia was the 
most common type of infection in both CDI and MDI and ac-
counted for 60.5% of the SBI episodes, and both bacteremia 
(n = 9) and urinary tract infection (n = 8) were frequently ob-
served. In addition, non-neutropenic fever was frequently ob-
served (n = 75) whereas neutropenic fever accounted for only 6 
episodes (7.4%). Most of the SBI episodes (62 of 81) were appro-
priately treated with systemic antibiotics although the subse-
quent bortezomib courses were postponed in 31 episodes and 
interrupted in 9 episodes. Among total 19 patients died during 
the bortezomib-based treatment (19.3% of overall mortality 
rate), 12 patients died from infection with at least partial response 
to bortezomib and 7 patients died from infection in progressive 
or refractory status.
 Variable pathogens were identified in 30 MDI cases. Gram-
negative bacteria (n = 21) were more prevalent than gram-pos-
itive bacteria (n = 9). Acinetobacter baumannii (n = 6), Esche-
richia coli (n = 5), Klebsiella species (n = 4), coagulase-negative 
Staphylococci (n = 4), and Staphylococcus aureus (n = 3) were 
common pathogens.
Risk factors for developing SBI in 98 MM patients
To identify the risk factors for developing SBI in 98 patients, three 
types of analysis were introduced in this study. An analysis of 
the risk factors was performed 1) during the total period of bort-
ezomib-based treatment, 2) within 3 months from initiation of 
therapy, and 3) in the first 2 treatment courses. The clinical and 
myeloma-associated variables evaluated are presented in Table 
3. Multivariate analysis showed that only poor performance sta-
tus (Eastern Cooperative Oncology Group [ECOG] performance 
status ≥ 2) had statistical significance as a risk factor for devel-
oping SBI during the total period of bortezomib-based treatment 
(hazard ratio [HR], 5.365; 95% confidence interval [CI], 2.004-
14.364, P = 0.001, Table 3), within 3 months (HR, 4.976; 95% CI, 
1.817-13.624, P = 0.002), and within 2 courses (HR, 8.652; 95% 
CI, 2.845-26.310, P < 0.001).
Risk factors for developing SBI during the 427 courses of 
bortezomib-based treatment
The risk factors that changed during each treatment course were 
evaluated. The incidence of SBI was higher in the treatment 
courses where poor performance status (ECOG ≥ 2, 34.2% vs. 
10.6%, P < 0.001), pretreatment lymphocytopenia (ALC < 1.0 ×  
109/L, 25.1% vs. 14.6%, P = 0.005), and pretreatment hypoalbu-
minemia (serum albumin < 3.5 g/dL, 36.0% vs. 11.1%, P < 0.001) 
were reported, and early in the course of treatment (≤ 2 cours-
es, 28.4% vs. 11.9%, P < 0.001) compared with other courses. 
There was no significant change of the median ALC at each cy-
cle during bortezomib-based treatment (P = 0.983). According 
to the univariate analysis, poor performance status (P < 0.001), 
pretreatment lymphocytopenia (P = 0.007), pretreatment hy-
poalbuminemia (P < 0.001), and early course of treatment (P <  
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Fig. 1. Number of severe bacterial infections (SBI) episodes during treatment with the 
bortezomib-based regimens. Cumulative numbers of SBI are presented at the bottom 
of the bars, and numbers of SBI episodes at each course are presented at the top of 
the bars.
Table 2. Eighty-one episodes of severe bacterial infections during chemotherapy with 
the bortezomib-containing regimens
Clinical conditions No. (%) of episodes 
Classification of infection
Clinically documented infection
   Pneumonia
   Colitis
   Parotitis
Microbiologically documented infection
   Pneumonia
   Bacteremia
   Urinary tract infection
   Colitis
Fever of unknown origin
42 (51.9)
37
  4
  1
30 (37.0)
12
  9
  8
  1
9 (11.1)
Type of fever 
Neutropenic fever
   Grade 3
   Grade 4
   Grade 5
Non-neutropenic fever
   Grade 3
   Grade 4
   Grade 5
6 (7.4)
  3
  2
  1
75 (92.6)
47
10
18
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Table 3. Univariate and multivariate analysis for the risk of developing severe bacterial infection during bortezomib-based treatment in 98 patients (patient-based analysis)
Variables
Univariate Multivariate
P value P value HR 95% CI
Variables at the time of diagnosis
Age > 65 0.235
Male 0.028 0.130 0.503 0.207-1.225
Immunophenotype (IgA vs. others) 0.941
DS stage at diagnosis (III vs. others) 0.618
ISS stage at diagnosis (III vs. others) 0.414
Plasma cells in bone marrow at diagnosis ( > 50%) 0.142
Variables at the time of bortezomib treatment initiation
ECOG ≥ 2 0.001 0.001 5.365 2.004-14.364
Relapsed/refractory status (vs. newly diagnosed) 0.925
Prior receipt of autologous stem cell transplantation 0.797
Monoclonal protein ≥ 3.0 g/dL 0.941
Number of uninvolved Ig reductions ≥ 1 (vs. 0) 0.458
White blood cell count ( < 4.0 × 109/L) 0.680
Absolute neutrophil count ( < 1.5 × 109/L) 0.152
Absolute lymphocyte count ( < 1.0 × 109/L) 0.670
Hemoglobin level ( < 8.5 g/dL) 0.113
Platelet count ( < 100 × 109/L) 0.254
Albumin ( < 3.5 g/dL) 0.368
Creatinine ( ≥ 2.0 mg/dL) 0.358
Ferritin ( ≥ 1,000 ng/mL) 0.639
Current pathologic fracture 0.217
Prior lines of therapy ≥ 2 (vs. < 2) 0.704
Prior radiation therapy 0.124
Prior vertebroplasty 0.178
Prior bacterial infection 0.243
Presence of central venous catheter 0.803
Mean dose of administered glucocorticoid per course ( > 160 mg dexamethasone equivalent dose) 0.423
Combination treatment regimens (VMP or PAD) (vs. VD) 0.982
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; DS, Durie-Salmon; ISS, International Scoring System; VD, bortezomib-dexamethasone; 
VMP, bortezomib melphalan prednisolone; PAD, bortezomib doxorubicin dexamethasone; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; 
Ig, immunoglobulin.
Table 4. Univariate and multivariate analysis for the risk of developing severe bacterial infections during the 427 courses of the bortezomib-based treatment according to the 
clinical and laboratory characteristic at the beginning of each course (course-based analysis)
Variables
Univariate Multivariate
P value P value HR 95% CI
ECOG  ≥ 2 < 0.001 < 0.001 3.920 2.305-6.666
Early courses of therapy ( ≤ 2 courses) < 0.001 < 0.001 2.782 1.633-4.740
Monoclonal protein  ≥ 3.0 g/dL* 0.061
Number of uninvolved immunoglobulin reductions ( > 1) 0.268
Pretreatment white blood cell count ( < 4.0 × 109/L) 0.362
Pretreatment absolute neutrophil count ( < 1.5 × 109/L) 0.152
Pretreatment absolute lymphocyte count ( < 1.0 × 109/L) 0.007 0.043 1.728 1.016-2.937
Pretreatment hemoglobin level ( < 8.5 g/dL)* 0.013
Pretreatment platelet count ( < 100 × 109/L) 0.754
Pretreatment albumin ( < 3.5 g/dL)* < 0.001
Pretreatment creatinine ( ≥ 2.0 mg/dL) 0.383
Pretreatment ferritin ( ≥ 1,000 ng/mL) 0.832
Dose of glucocorticoid used at each course ( >160 mg dexamethasone equivalent dose) 0.151
*These variables were excluded in the multivariate analysis because of collinearity with early courses of therapy. HR, hazard ratio; CI, confidence interval; ECOG, Eastern Coop-
erative Oncology Group. 
0.001) were significantly associated with the development of 
SBI in each treatment course (Table 4). In the multivariate logis-
tic analysis, poor performance status (HR, 3.920; 95% CI, 2.305-
6.666, P < 0.001), early course of treatment (HR, 2.782; 95% CI, 
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1.633-4.740, P < 0.001), and pretreatment lymphopenia (HR; 
1.728; 95% CI, 1.016-2.937, P = 0.043) were risk factors for de-
veloping SBI in each treatment course. The probability of devel-
oping SBI was 5.1% in the absence of risk factors, 14.9% with 1 
risk factor, 23.9% with 2 risk factors, and 59.5% with 3 risk fac-
tors (P < 0.001, Fig. 2). 
Treatment outcomes
The overall response rate (at least partial response) of the SBI 
group was 51.9%, which was lower than that of the non-SBI group 
(70.5%, P = 0.048). Among the 98 enrolled patients, 48 patients 
(49.0%) died during the median follow-up period from the ini-
tiation of bortezomib treatment of 6.3 months (range, 0.5-57.1 
months). The median OS was significantly higher in the non-SBI 
group compared with the SBI group (30.1 months vs. 6.1 months, 
P = 0.004) although PFS was not significantly different between 
the two groups (21.9 months vs. 18.1 months, P = 0.418).
 In the 57 patients aged less than 65 year, 14 of the 24 (58.3%) 
patients in the non-SBI group received autologous stem cell trans-
plantation, but only 6 of 33 (18.2%) patients in the SBI group re-
ceived autologous stem cell transplantation (P = 0.002). Among 
the patients aged below 65 year, the SBI group showed a signifi-
cantly shorter median OS compared with the non-SBI group 
(11.2 months vs. not reached, P = 0.016) and a significantly short-
er PFS compared with the non-SBI group (6.0 months vs. 24.4 
months, P = 0.015, Fig. 3).
DISCUSSION
Herein we demonstrate that poor performance status (ECOG 
≥ 2), early course of treatment (≤ 2 courses), and pretreatment 
lymphopenia (ALC < 1.0 × 109/L) are risk factors for developing 
SBI in MM patients treated with bortezomib-based regimens. 
More than half (59.5%) of the patients with all three risk factors 
developed SBI whereas only 5.1% of the patients without risk 
factors developed SBI. Therefore, we could expect the risk of 
developing SBI at the subsequent course of bortezomib-based 
treatment. It would be beneficial to manage MM patients sus-
ceptible to SBI. Although we found the poor performance sta-
tus at diagnosis as significant risk factor for developing SBI dur-
ing the total period of bortezomib-based treatment, the assess-
ment of the risk factors in each course of bortezomib-based treat-
ment would be more suitable to predict the exact risk of devel-
oping SBI in subsequent bortezomib-based treatments because 
the clinical and laboratory parameters changed in each treat-
ment course.
 The early course of treatment (≤ 2 courses) was defined as a 
Fig. 2. Probability of severe bacterial infection according to the number of risk factors 
in each bortezomib course. Three risk factors are poor performance status (ECOG ≥ 
2), early course of treatment ( ≤ 2 courses), and pretreatment lymphopenia (absolute 
lymphocyte count < 1.0 × 109/L).
Number of risk factors
 0 1 2 3
P < 0.001
5.1%
14.9%
23.9%
59.5%
Fig. 3. Overall survival (A) and progression-free survival (B) after the bortezomib-based treatment of 57 MM patients under 65 years of age according to the presence of severe 
bacterial infection (SBI). MM, multiple myeloma; SBI group, patients who developed SBI; Non-SBI group, patients who did not experience SBI.
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risk factor for SBI in this analysis because of hypogammaglobu-
linemia associated with high tumor burden in the early period 
of treatment (21). A decreased level of uninvolved immunoglob-
ulins in MM serves as a risk factor for infection with encapsu-
lated bacteria (e.g., Streptococcus pneumoniae or Haemophilus 
influenzae) (7). The degree of immunoglobulin suppression 
and disease stage are interrelated (20), and decreased levels of 
uninvolved immunoglobulin have been known as an indepen-
dent prognostic factor for shorter OS (21). Many studies conduct-
ed before the development of the novel agents demonstrated 
the increased risk of infections in the early period of treatment, 
particularly within 4-6 months following treatment, and the de-
creased risk of infections after achieving a favorable response to 
treatment (16,22,23). Because of the serial reduction of tumor 
burden in subsequent courses of the bortezomib-based treat-
ment, the risk of SBI was significantly higher in the first two cour-
ses of bortezomib-based treatment in this study.
 Poor performance status has been reported as a poor prog-
nostic factor for survival (1,24), which increases treatment-re-
lated toxicity and/or the risk of infection in MM (25). Because 
the bortezomib-based treatment for patients with poor perfor-
mance status is usually performed in the inpatient setting, these 
patients can be easily exposed to a variety of nosocomial infec-
tions. Cesana et al. reported a higher incidence of nosocomial 
infections in MM patients treated with VAD regimen in the in-
patient setting compared with in the outpatient setting (6% vs. 
0%) (16). Gram-positive encapsulated bacteria are known to be 
predominant pathogens in patients with MM. The incidence of 
infection with gram-negative bacilli increased after using alkyl-
ating agents or novel antimyeloma agents (7,26). In this study, 
gram-negative bacteria accounted for 70% of MDI cases and the 
most common pathogen was Acinetobacter baumannii (n = 7), 
a major pathogen of hospital-acquired pneumonia (27).
 Lymphopenia at the beginning of each course was a novel 
risk factor for SBI in this study. It is generally considered to be 
associated with viral and fungal infections (28). However, sev-
eral studies reported lymphopenia as a marker of severe sepsis 
and septic shock (19,29). Lymphopenia indicates a preexisting 
immunosuppressed condition. Therefore, patients with lym-
phopenia have inadequate immunologic reactions and conse-
quently are vulnerable to bacterial infection. Until now, there is 
limited data about lymphopenia as a predictive factor for infec-
tion in MM. Jung et al. analyzed the data from 139 patients treat-
ed with bortezomib and observed that lymphopenia levels of 
< 0.8 × 109/L at diagnosis were a risk factor for SBI. Total 30 out 
of the 74 patients (40.5%) with lymphopenia developed SBI (30). 
In this study, the incidence of SBI in treatment courses with 
lymphopenia (< 1.0 × 109/L) was 42.0%, which was higher than 
the incidence of SBI in courses without lymphopenia (14.6%, 
P = 0.007). Considering the change of lymphocyte counts in 
each treatment course, the impact of lymphopenia at the be-
ginning of each course in this study would be more valuable in 
clinical application.
 Corticosteroid therapy has been reported to increase the in-
cidence of infections with intracellular pathogens such as Liste-
ria monocytogenes, various fungal species, and herpes viruses 
(31). The risk for infection is associated with the dose and the 
duration of therapy, and doses exceeding 20 mg of prednisone 
equivalent per day or a cumulative dose of more than 700 mg of 
prednisone can increase the risk of infections (22). Large cumu-
lative doses of corticosteroids are frequently used during MM 
treatments and contribute to increase the risk of infection. A re-
cent clinical trial compared lenalidomide plus low-dose dexa-
methasone (40 mg once a week, on days 1, 8, 15, and 22, every 
28 days), lenalidomide plus high-dose dexamethasone (40 mg 
per day for four consecutive days on days 1-4, 9-12, and 17-20, 
every 28 days), and reported a higher incidence of infection in 
the high-dose dexamethasone arm (16%) compared with the 
low-dose dexamethasone arm (9%). The trial demonstrated a 
significantly decreased incidence of infectious complications 
and resultant improved OS in low-dose dexamethasone group 
(32). In this study, there was a trend to lower incidence of SBI in 
courses with lower doses of concomitant corticosteroid than 
higher doses of corticosteroid. The incidence of SBI was 18.0% 
in course with lower doses of corticosteroid (≤ 160 mg of dexa-
methasone equivalent dose) and 26.5% in course with higher 
doses of corticosteroid (> 160 mg of dexamethasone equivalent 
dose) (P = 0.151). However, we could not demonstrate a rela-
tionship between corticosteroid doses and the incidence of SBI 
because most of our patients received relatively low doses of 
corticosteroids during bortezomib-based treatment. Of the pa-
tients who received bortezomib combined with dexamethasone, 
the mean dose of dexamethasone was 157.45 ± 113.94 mg, which 
was very similar to the dose of low-dose dexamethasone, and 
only 6% of the patients received high-dose dexamethasone. 
Therefore, our cohort would be considered as a homogenous 
population that is suitable for assessing the risk factors for SBI.
 The prophylactic use of antibiotics for reducing the bacterial 
infections has been proposed in MM. However, evidence about 
the prophylactic use of antibiotics in non-neutropenic MM pa-
tients is still inconclusive (33) whereas the prophylactic use of 
fluoroquinolone has been recommended by the National Com-
prehensive Cancer Network (34). The emergence of resistance 
to antibiotics as well as their efficacy and safety are concerns 
with regard to the prophylactic antibiotics (35). Therefore, the 
prophylactic use of antibiotics should not be recommended to 
all MM patients but only to those at increased risk of bacterial 
infection. In addition, adjustments in the corticosteroid dose in 
patients with high risk of SBI in each treatment course can be a 
good strategy to decrease the incidence of treatment-related in-
fectious complications. Therefore, further prospective studies 
are needed to elucidate the effectiveness of the prophylactic use 
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of antibiotics in MM patients and to assess the potential risks 
and benefits of using lower doses of corticosteroids.
 One of the limitations of this study is its retrospective nature. 
The prophylactic antibiotics and the corticosteroid dose were 
inconsistently administered depending on the patient’s situa-
tion. Therefore, the assessment of the risk of SBI after removing 
these confounding factors was limited although these factors 
might affect the risk of SBI. Although the SBI rates were not sta-
tistically different between the different regimens adopted (60.0% 
for VMP, 46.7% for PAD, and 58.6% for VD regimen), the rate 
obtained in this study was somewhat higher than that of other 
studies (11,21,36). Because many of the patients in this study 
had a relatively poor performance status (36.8%) at the time of 
bortezomib initiation, the high incidence of SBI in this study 
may be attributed to this factor.
 In conclusion, the three risk factors for developing SBI iden-
tified in the present study were the early course of therapy, poor 
performance status, and lymphopenia at the beginning of each 
treatment course in MM patients treated with bortezomib-based 
regimen. Therefore, patients with these risk factors should be 
more closely monitored for developing bacterial infections dur-
ing subsequent bortezomib-based treatments. Risk-adapted 
approaches such as the prophylactic use of antibiotics or modi-
fication of the corticosteroid dose should be considered to re-
duce the incidence of bacterial infection in those patients. Fur-
ther prospective studies are needed to support the implemen-
tation of effective preventive strategies against bacterial infection.
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